1. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094-108. doi: 10.1016/S0140-6736(10)60826-4.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19. doi: 10.1056/NEJMra1004965.
3. Joseph A, Brasington R, Kahl L, Ranganathan P, Cheng TP, Atkinson J. Immunologic rheumatic disorders. J Allergy Clin Immunol. 2010;125:S204-15. doi: 10.1016/j.jaci.2009.10.067.
4. Vignot S, Spano JP. Matrix metalloproteinases. Target Ther Oncol. 2007:315-32.
5. Ribbens C, Martin y Porras M, Franchimont N, Kaiser M, Jaspar J, Damas P, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: Relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002;61:161-6. doi.org/10.1136/ard.61.2.161
6. Wu JJ, Lark MW, Chun LE, Eyre DR. Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J Biol Chem. 1991;266:5625-8. doi: 10.1016/S0021-9258(19)67640-4.
7. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992;267:3581-4. doi: 10.1016/S0021-9258(19)50563-4.
8. Okada Y. Matrix-degrading metalloproteinases and their roles in joint destruction. Mod Rheumatol. 2000;10:121-8. doi: 10.3109/s101650070018.
9. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis. 2000;59:455-61. doi: 10.1136/ard.59.6.455.
10. Cawston T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today. 1998;4:130-7. doi: 10.1016/S1357-4310(97)01192-1.
11. Lerner A, Neidhöfer S, Reuter S, Matthias T. MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32:550-62. doi: 10.1016/j.berh.2019.01.006.
12. Kobayashi A, Naito S, Enomoto H, Shiomoi T, Kimura T, Obata K, et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med. 2007;131:563-70. doi: 10.5858/2007-131-563-SLOMMS.
13. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57:163-72. doi: 10.1124/pr.57.2.3.
14. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21:S179-85
15. Schweitzer BI, Dicker AP, Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J. 1990;4:2441-52. doi: https://doi.org/10.1096/fasebj.4.8.2185970.
16. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Jt Bone Spine [Internet]. Elsevier Masson SAS. 2019;86:301-7. Available from: http://dx.doi.org/10.1016/j.jbspin.2018.07.004.
17. Van Ede AE, Laan RFJM, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998;27:277-92. doi: 10.1016/S0049-0172(98)80049-8.
18. Van Ede AE, Laan RFJM, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44:1515-24. doi: 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7.
19. Chan ESL, Cronstein BN. Methotrexatehow does it really work? Nat Rev Rheumatol. 2010;6:175-8. doi: 10.1038/nrrheum.2010.5.
20. Merrill JT, Shen C, Schreibman D, et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes. A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 2007;40:1308-15. doi: 10.1002/art.1780400716.
21. Koshiba M, Kosaka H, Nakazawa T, Hayashi N, Saura R, Kitamura N, Kumagai S. 2-chloroadenosine but not adenosine induces apoptosis in rheumatoid fibroblasts independently of cell surface adenosine receptor signalling. Br J Pharmacol. 2002;135:1477-86. doi: 10.1038/sj.bjp.0704612.
22. Stamp LK, Frampton C, Hazlett J, et al. Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther. 2012;14:1-9. doi: 10.1186/ar3871.
23. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 1997;90:1600-10.
24. Koshiba M, Rosin DL, Hayashi N, Linden J, Sitkovsky MV. Patterns of A(2A) extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A(2A) receptor monoclonal antibodies. Mol Pharmacol. 1999;55:614-24.
25. Chao PZ, Hsieh MS, Cheng CW, Lin YF, Chen CH. Regulation of MMP-3 expression and secretion by the chemokine eotaxin-1 in human chondrocytes. J Biomed Sci. 2011;18:86. doi: 10.1186/1423-0127-18-86.
26. Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S, Shiozawa S. MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy. Arthritis Res Ther. 2016;18:55. doi: 10.1186/s13075-016-0948-7.
27. Sun HB, Yokota H. Messenger-RNA expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and transcription factors in rheumatic synovial cells under mechanical stimuli. Bone. 2001;28:303-9. doi: 10.1016/S8756-3282(00)00454-3.
28. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 1999;58:691-7. doi: 10.1136/ard.58.11.691.
29. Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, Borea PA. A 3adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res Ther. 2011;13:R197. doi: 10.1186/ar3527.
30. Vincenzi F, Padovan M, Targa M, Corciulo C, Giacuzzo S, Merighi S, et al. A2A adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. PLOS ONE. 2013;8:e54195. doi: 10.1371/journal.pone.0054195.
31. Noh EM, Kim JS, Hur H, Park BH, Song EK, Han MK, et al. Cordycepin inhibits IL-1β-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2009;48:45-8. doi: 10.1093/rheumatology/ken417.
32. Jia Q, Wang T, Wang X, Xu H, Liu Y, Wang Y, et al. Astragalin suppresses inflammatory responses and bone destruction in mice with collagen-induced arthritis and in human fibroblast-like synoviocytes. Front Pharmacol. 2019;10:94. doi: 10.3389/fphar.2019.00094.
33. Han SK, Jeon SJ, Miyazawa K, Yi SY, Yoo YS. Enhancement of anti-inflammatory tendency by SB203580, p38α specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A. Rheumatol Int. 2006;26:972-8. doi: 10.1007/s00296-006-0109-4.
34. Zhang X, Zhang D, Wang Q, Guo X, Chen J, Jiang J, et al. Sprouty2 inhibits migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by down-regulating ATF2 expression and phosphorylation. Inflammation. 2021;44:91-103. doi: 10.1007/s10753-020-01311-z.
35. Zer C, Sachs G, Shin JM. Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-α signaling. Physiol Genomics. 2007;31:343-51. doi: 10.1152/physiolgenomics.00080.2007.
36. Zhao Y, Qin Y, Wu S, Huang D, Hu H, Zhang X, Hao D. Mesenchymal stem cells regulate inflammatory milieu within degenerative nucleus pulposus cells via p38 MAPK pathway. Exp Ther Med. 2020;20:22. doi: 10.3892/etm.2020.9150.
37. Baud V, Karin M, Karin M. Signal transduction by TNF and its relatives. Trends Cell Biol. 2001;11:372-7.
38. Koshiba M, Nakamachi Y, Kosaka H, Nakazawa T, Tsuji G, Kumagai S. Modification of cytokine milieu by A2A adenosine receptor signaling-possible application for inflammatory diseases. Nucleosides Nucleotides Nucleic Acids. 2004;23:1101-6. doi: 10.1081/NCN-200027368.
39. Milne GR, Palmer TM. Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. ScientificWorldJournal. 2011;11:320-39. doi: 10.1100/tsw.2011.22.
40. Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, et al. Baseline serum MMP-3 levels in patients with rheumatoid arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther. 2012;14:R30. doi: 10.1186/ar3734.
41. Ma JD, Wei XN, Zheng DH, Mo YQ, Chen LF, Zhang X, et al. Continuously elevated serum matrix metalloproteinase-3 for 3 ~ 6 months predicts one-year radiographic progression in rheumatoid arthritis: a prospective cohort study. Arthritis Res Ther. 2015;17:289. doi: 10.1186/s13075-015-0803-2.
42. Conway JG, Wakefield JA, Brown R, Marron BE, Sekut L, Stimpson SA, et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med. 1995;182:449-57. doi: 10.1084/jem.182.2.449.
43. Ishikawa T, Nishigaki F, Miyata S, Hirayama Y, Minoura K, Imanishi J, et al. Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. Br J Pharmacol. 2005;144:133-43. doi: 10.1038/sj.bjp.0706054.